ADT Use Linked With Higher Risk of Alzheimer's Disease
Use of androgen deprivation therapy may be associated with an increased risk of Alzheimer’s disease.
Use of androgen deprivation therapy (ADT) may be associated with an increased risk of Alzheimer's disease, according to a recent study published online ahead of print in the Journal of Clinical Oncology.1
Kevin Nead, MD, MPhil , of the Hospital of the University of Pennsylvania in Philadelphia, and colleagues conducted a retrospective cohort study of 16 888 men with prostate cancer in a previously validated and implemented text-processing pipeline.
They tested the effect of ADT on risk of Alzheimer's using 1 to 5 propensity score-matched and traditional multivariable-adjusted Cox proportional hazards models.
Among 2397 men who received ADT with a median follow-up of 2.7 years, both hazards models suggested a statistically significant association between ADT use and Alzheimer's disease risk.
RELATED: Initial Gleason Score Does Not Impact Abiraterone Benefit in Prostate Cancer
They also observed a statistically significant increase in risk of Alzheimer's with higher duration of ADT.
“This study demonstrates the utility of novel methods to analyze electronic medical record data to generate practice-based evidence,” the authors concluded.
- Nead KT, Gaskin G, Chester C, et al. Androgen deprivation therapy and future Alzheimer's disease risk [published online ahead of print December 7, 2015]. J Clin. Oncol. doi: 10.1200/JCO.2015.63.6266.